| Chitosan-based nanoparticles against viral infections H Boroumand, F Badie, S Mazaheri, ZS Seyedi, JS Nahand, M Nejati, ... Frontiers in Cellular and Infection Microbiology 11, 643953, 2021 | 124 | 2021 |
| Gynecologic cancers and non-coding RNAs: epigenetic regulators with emerging roles ZS Razavi, V Tajiknia, S Majidi, M Ghandali, HR Mirzaei, N Rahimian, ... Critical reviews in oncology/hematology 157, 103192, 2021 | 110 | 2021 |
| Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches F Badie, M Ghandali, SA Tabatabaei, M Safari, A Khorshidi, ... Frontiers in Oncology 11, 624759, 2021 | 57 | 2021 |
| Therapeutic targeting of TRAIL death receptors F Di Cristofano, A George, V Tajiknia, M Ghandali, L Wu, Y Zhang, ... Biochemical Society Transactions 51 (1), 57-70, 2023 | 30 | 2023 |
| An update on the effects of probiotics on gastrointestinal cancers A Davoodvandi, F Fallahi, OR Tamtaji, V Tajiknia, Z Banikazemi, ... Frontiers in pharmacology 12, 680400, 2021 | 27 | 2021 |
| Targeting apoptotic pathways for cancer therapy X Tian, PR Srinivasan, V Tajiknia, AFSS Uruchurtu, AA Seyhan, ... The Journal of clinical investigation 134 (14), 2024 | 13 | 2024 |
| Targeting immune suppression after atr inhibition WS El-Deiry, M Ghandali US Patent App. 18/677,223, 2024 | | 2024 |
| Tumor treating fields induce the integrated stress response, alter the transcriptional signatures of cellular metabolism, and modulate immune-related cytokines dependent and … PR Srinivasan, A George, C Chou, M Pinho-Schwermann, M Ghandali, ... Cancer Research 84 (6_Supplement), 587-587, 2024 | | 2024 |
| The anti-tumor efficacy and immune effects of combining of ceralasertib, an oral ATR kinase inhibitor, with imipridones, in prostate cancer treatment in vitro and in vivo YL Xia, L Zhang, M Ghandali, MP Schwermann, W El-Deiry Cancer Research 84 (6_Supplement), 5559-5559, 2024 | | 2024 |
| Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib M Ghandali, P Srinivasan, Y Xia, ET Wong, RW Sobol, L zhou, ... Cancer Research 84 (6_Supplement), 7591-7591, 2024 | | 2024 |
| TIC10/ONC201 in combination with ceralasertib exhibits potent synergy in high grade serous ovarian cancer cells M Ghandali, KM Selvi, KE Huntington, A George, A Ochsner, BA Carneiro, ... Cancer Research 83 (7_Supplement), 5512-5512, 2023 | | 2023 |
| PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells M Ghandali, KE Huntington, praveen Srinivasan, DS Dizon, SL Graff, ... Cancer Research 83 (7_Supplement), 1066-1066, 2023 | | 2023 |
| Looking into a New Challenge, DKA and Covid-19 A Review on Pediatric DKA Cases during New Coronavirus Pandemic Who is to Blame, the Virus or Health System RP A Ahmadvand, V Tajiknia, M Ghandali, A Afrasiabi J. Endocrinology and Disorders 5 (6), 6, 2021 | | 2021 |
| Evaluation of Predicting Factors on Patients’ Outcome Underwent Esophageal Cancer Surgery Treatment, A Single Institution, A Decade of Study, Firoozgar Hospital, Tehran, Iran … G Tajiknia v,Baghaiw M Japanese Journal of Gastroenterology and Hepatology 7 (3), 1-9, 2021 | | 2021 |
| A Brief Review on Covid-19 and Flavonoids Antiviral Effects. MF Ghandali M,Tajiknia V,Ahmadvand A Journal of Corona Virus 1 (3), 2021 | | 2021 |
| Journal of Clinical Images and Medical Case Reports A Ahmadvand, H Seifmanesh, M Ghandali, A Afrasiabi, V Tajiknia, ... | | 2021 |
| A review on covid-19 and acute ischemic stroke, malignant cerebral edema & decompressive hemicraniectomy: A perfect storm; tackling this crisis by understanding it A Ahmadvand, H Seifmanesh, M Ghandali, A Afrasiabi, V Tajiknia, ... | | |
